Ozari Health review
The lowest figure is a starter block for people new to GLP-1, and the full plan table sits behind it.
The verdict
Ozari Health advertises semaglutide from $86 a month, which is a three-month starter restricted to first-time GLP-1 users and charged $257 up front. Its own plan table lists monthly at $175.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- From
- From $175/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Ozari Health sells both molecules by injection across four plan lengths, with a separate entry block that only some readers are eligible for.
Who writes the prescription, and what do they see?
A prescription precedes shipping and the clinician is not described. The eligibility rule on the starter block is clinical in form and commercial in effect: it sorts buyers by whether they have taken a GLP-1 before.
The compare-all-plans table is the honest document here, and it is the one a reader has to find. It lists monthly, quarterly, semi-annual and annual rates for both molecules, and the advertised figure appears on none of them because it belongs to a block sold once.
What happens when the dose goes up?
Nothing states what any rung does at a higher dose, though the site notes figures range upward by dose and plan. So two variables move and only one of them is published as a ladder.
What the price includes
The semaglutide table reads $175 monthly, $145 quarterly, $120 semi-annual and $99 annual. Tirzepatide reads $235, $199, $175 and $140. The starter blocks are $257 and $375 charged at once, and both are first-time only. A returning buyer should plan from $175 or $235, not from the advertised figure.
What it claims, and what it cites
Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is.
Where it holds up, and where it does not
- Strength: A full four-rung table for both molecules
- Strength: Shipping stated as included
- Strength: The starter block's total is published
- Limitation: The advertised figure is first-time only
- Limitation: Monthly costs twice the headline
- Limitation: Figures also range upward by dose
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about Ozari Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader new to GLP-1 who will read the plan table before the second quarter.
- Wrong for
- A returning buyer, who cannot reach the advertised figure at all.
The evidence behind what Ozari Health prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Ozari Health compares
| Seller | Who it suits | Go |
|---|---|---|
 Oria Meds | Readers who will commit six months and know which rung the headline is | See Oria Meds → |
 Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | See Options Medical Weight Loss → |
 Open Water Rx | Readers who want one all-inclusive figure with no code attached | See Open Water Rx → |
More GLP-1 telehealth sellers reviews: HealFastRxHelix Wellness RxHone HealthHormonally BalancedJM Integrated HealthKairoRx
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Can I get $86 a month?
- Only as a first-time GLP-1 user, and only as a three-month starter charged $257 up front.
- What does the monthly plan cost?
- $175 for semaglutide and $235 for tirzepatide, per the compare-all-plans table.
- How low do the longer plans go?
- $99 a month for semaglutide on the annual rung and $140 for tirzepatide.
- Is Ozari Health expensive compared with other GLP-1 telehealth sellers?
- Ozari Health publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ozari Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.